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Abstract
Antibodies specific for glucose-6-phosphate isomerase (G6PI)
from T-cell receptor transgenic K/BxN mice are known to induce
arthritis in mice, and immunization of DBA/1 mice with G6PI led
to acute arthritis without permanent deformation of their joints.
Because rheumatoid arthritis is a chronic disease, we set out to
identify the capacity of G6PI to induce chronic arthritis in mice.
Immunization with recombinant human G6PI induced a
chronically active arthritis in mice with a C3H genomic
background, whereas the DBA/1 background allowed only
acute arthritis and the C57BL/10 background permitted no or
very mild arthritis. The disease was associated with the major
histocompatibility region sharing an allelic association similar to
that of collagen-induced arthritis (i.e. q > p > r). All strains
developed a strong antibody response to G6PI that correlated
only in the C3H.NB strain with arthritis severity. Similarly, a weak
response to type II collagen in a few mice was observed, which
was associated with arthritis in C3H.NB mice. Mice on the C3H
background also developed ankylosing spondylitis in the
vertebrae of the tail. Both C3H.Q and B10.Q mice deficient for
B cells were resistant to arthritis. We conclude that G6PI has
the ability to induce a chronic arthritis, which is MHC associated
and B-cell dependent. Thus, there are striking similarities
between this and the collagen-induced arthritis model.
Introduction
Glucose-6-phosphate isomerase (G6PI) is a widely expressed
protein with multiple functions. It is an essential cytosolic
enzyme in the energy cycle and has glycolytic activity, but it
also has additional functions as an extracellular signalling mol-
ecule. Thus, G6PI is also known as AMF (autocrine motility
factor) and neuroleukine, and may play roles in both cancer
and autoimmunity [1,2].
Coincidentally, it was found that G6PI plays an essential role
in the development of arthritis in mice. This originally stemmed
from the observation that a bovine pancreas ribonuclease spe-
cific T-cell receptor transgenic mouse crossed with NOD mice
(the so-called K/BxN mouse) spontaneously developed arthri-
tis. Through a series of elegant experiments it was demon-
strated that this transgenic T-cell receptor recognized G6PI
within the context of major histocompatibility complex (MHC)
class II molecule Ag7 [3,4]. The transgenic autoreactive T cells
triggered autoreactive B cells to produce arthritogenic anti-
bodies specific to G6PI [4-6]. After transferring G6PI-reactive
serum from arthritic K/BxN mice, these antibodies bound to
peripheral joints and induced arthritis in a manner strikingly
similar to that shown previously for antibodies to the cartilage-
specific antigen collagen type II (CII) [7,8]. B-cell activation in
response to G6PI appeared to occur primarily in lymph nodes
draining the joints [9], indicating that recognition of G6PI is
joint specific. The reason for this specificity is not apparent
because the G6PI protein is a ubiquitous protein.
Even though there are inconsistent data regarding the role of
G6PI in rheumatoid arthritis (RA) [10-13], it appears that anti-
bodies to G6PI occur predominantly in patients with Felty's
syndrome – a variant of RA [14]. It is still unclear whether this
is a unique phenomenon of Felty's syndrome or whether it
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reflects a generalized higher autoreactivity in these patients.
Support for the latter comes from a study using affinity purified
sera from arthritis patients that compared different kinds of
arthritides and suggested a role for G6PI antibodies [15].
G6PI is nevertheless an interesting autoantigen and may rep-
resent a unique pathway leading to aggressive subtypes of
RA. It is thus interesting to investigate this model further and
to compare it with other models, such as the classic collagen-
induced arthritis (CIA) model [16]. Here we show that immuni-
zation with G6PI leads to a chronically active arthritis in mice
with genes from the C3H background, and that susceptibility
is both controlled by the MHC region and dependent on B
cells.
Materials and methods
Mice
The mouse strains were bred and used in the animal facility of
the Section for Medical Inflammation Research (University of
Lund, Lund, Sweden). Mice of DBA/1J and C3H.NB origins
were from Jackson Laboratories (Bar Harbor, Maine, USA),
and those of B10.Q, B10.P and B10.RIII origins were from Dr
Jan Klein (Max-Planck-Institut für Biologie, Abteilung
Immungenetik, Tübingen, Germany). C3H.Q mice were estab-
lished through backcrossing (4n) of the H2q fragment derived
from an original C3H.Q mouse into C3H.NB [17]. The human
DR4 transgenic and the backcrossed B-cell deficient mouse
strains were described previously [18-20].
Experimental mice were matched for sex and age in all experi-
ments. The founder µMT mouse was kindly provided by Dr
Werner Müller (Institute of Genetics, Cologne, Germany),
which we backcrossed to B10.Q for 13 generations before
they were intercrossed for the experiment. C3H.Q µMT mice
were backcrossed for 10 generations and finally intercrossed.
The experiments were conducted in accordance with guide-
lines from the Swedish Ethical Committee.
Antigens
Recombinant human G6PI was produced as previously
described [21]. G6PI cDNA fragments were introduced into a
modified pQE100 expression vector for expression of His-
tagged proteins in Escherichia coli strain Bl21. Supernatants
of bacterial lysates were subjected to purification over a Ni-
NTA column (Qiagen, Hilden, Germany), in accordance with
the manufacturer's instructions. Using the same strategy,
human creatine kinase (hCK) and mouse G6PI (mG6PI) was
produced. The purity of proteins was checked using standard
SDS gels. Rat collagen type II (rCII) was prepared from
SWARM chondrosarcoma by pepsin digestion [22] and fur-
ther purified as described previously [23].
Immunization and arthritis scoring
An emulsion for immunization was made by sonication, using
an aliquot of human G6PI and complete Freund's adjuvant
(Difco, Detroit, MI, USA), resulting in an emulsion of 2 mg/ml
human G6PI. A total of 100 µl of the emulsion (200 µg G6PI)
was injected at the base of the tail in each mouse. For the titra-
tion experiments G6PI was diluted with phosphate-buffered
saline to adjust to the required concentration. In some experi-
ments mice were given an intradermal boost with 50 µg G6PI
in incomplete Freund's adjuvant. Mice were visually scored for
arthritis using an extended scoring protocol ranging from 1 to
15 for each paw, allowing a maximum score of 60 per mouse.
Each arthritic (red and swollen) toe and knuckle was scored as
1, whereas an affected ankle was scored as 5 (total: 15/paw)
[24].
Antibody analysis
Serum for analysis of antibody levels was taken at indicated
time points and at the end of all experiments. Serum was
diluted 1:1,000 for G6PI, mG6PI, hCK and 1:100 for rCII anti-
body analysis. ELISA Maxisorp plates (Nunc, Roskilde Den-
mark) were coated with 50 µl of 10 µg/ml of the recombinant
proteins or rat CII. The amounts of total specific IgG was
determined through quantitative ELISA using peroxidase-con-
jugated goat anti-mouse IgG (H+L; 115-035-062; Jackson
ImmunoResearch, West Grove, PA, USA) secondary antibod-
ies [25]. ABTS (2,2'-Azino-bis(3-Ethylbenzthiazoline-6-Sul-
fonic Acid), # 11204521001; Roche Diagnostics GmbH,
Penzberg, Germany) was used as substrate. Values were
measured at 405 nm and are expressed as optical density
values.
Histology
At the end of the experiments paws, knees, and tails were fix-
ated in 4% paraformaldehyde for 24 hours and decalcified
with EDTA. The paraffin sections were stained with haematox-
ylin and erythrosine [26].
Statistical analysis
Frequency of arthritis was analyzed using the χ2 test, and anti-
body levels and arthritis severity were analyzed using the
Mann-Whitney U-test. Disease score and antibody correla-
tions were analyzed using the Spearman rho correlation test
from the StatView software package (Version 5.0.1, SAS Insti-
tute Inc., Cary, NC, USA).
Results
Titration of the arthritogenic dose of G6PI
DBA/1 mice were used to confirm induction of arthritis using
human recombinant G6PI in our animal house and to titrate the
dose. Almost 100% of the mice developed arthritis upon
immunization with all of the doses used, although the severity
was dose dependent. With the lowest dose (100 µg) the
arthritis started as early as day 9 and subsequently progressed
to a severe arthritis peaking 2 weeks after immunization.
Thereafter the disease gradually resolved and no macroscopic
signs of arthritis were apparent at day 40 (Fig. 1a), enablingAvailable online http://arthritis-research.com/content/7/6/R1316
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mice to climb under the lids of their cages. The intermediate
dose of 200 µg per mouse, which resulted in arthritis in 100%,
was selected for further study.
Pronounced genetic control of chronic arthritis involving 
both MHC and non-MHC genes
G6PI immunization of different mouse strains resulted in
marked differences in arthritis susceptibility and severity. The
C3H.NB strain developed arthritis approximately 2 days later
than did DBA/1 mice. However, the arthritis in C3H.NB mice
was more severe and, most importantly, these mice developed
a chronically active inflammation that lasted throughout the
observation period of 90 days (Fig. 1b).
Histological analysis of joints at 90 days after immunization
showed active erosive inflammation (Fig. 2e,j). It should be
pointed out that only active inflammatory arthritis with redness
and oedema was evaluated for clinical scoring. Even though
the oedema declined over time in C3H mice, these animals still
had tissue depositions that rendered the joints dysfunctional.
There was also massive cell infiltration of the joint space caus-
ing erosion and destruction of bone and cartilage, as demon-
strated by histology (Fig. 2e,j). The destructive character of
this process was striking; for instance, it was even able to dis-
solve joint cartilage. Simultaneously, new bone formation
could be observed, creating large osteophytes. In contrast,
DBA/1 mice regained function of many finger joints without
Figure 1
Characterization of G6PI-induced arthritis Characterization of G6PI-induced arthritis. Shown are characteristics of glucose-6-phosphate isomerase (G6PI)-induced arthritis in different genetic 
backgrounds and major histocompatibility complex (MHC) congenics. (a) DBA/1 mice were immunized intradermally at the base of the tail with the 
indicated amounts of G6PI emulsified in complete Freund's adjuvant (CFA) to establish a dynamic immunization protocol allowing for an increase or 
decrease in disease severity. The course of disease was followed for 40 days after immunization. The graph shows the mean scores for all mice. Dis-
ease developed in 8/8 (400 µg/mouse), 9/9 (200 µg/mouse) and 8/9 (100 µg/mouse) mice. (b) After establishing the immunization protocol, mice 
with different MHC haplotypes and genetic backgrounds were immunized with 200 µg G6PI in CFA at the base of the tail. Active arthritis, character-
ized by redness and oedema, was scored over 90 days after immunization. Blood was drawn at day 40 for antibody analysis and the mice were 
boosted with human G6PI (50 µg/mouse in incomplete Freund's adjuvant) at day 48. The numbers of mice of each strain evaluated were as follows: 
(B10.Q × DBA/1)F1, n = 10; B10-Tg(DR4), n = 8; B10.P, n = 12; B10.Q, n = 26; B10.RIII, n = 6; C3H.NB, n = 9; and DBA/1, n = 10. (c) 
Because the MHC haplotype H-2p on the black background rendered mice resistant to G6PI-induced arthritis, the role of the beta chain of Ap was 
addressed on the highly susceptible C3H background. C3H.NB (H-2p; n = 21) and C3H.Q (H-2q; n = 19) mice were immunized intradermally with 
200 µg G6PI in CFA and scored for 73 days. At no time point was a significant difference noticed between the two MHC congenic strains. Only a 
tendency toward more chronic progression could be seen in the C3H.Q mice during the late phase. In all experiments, error bars indicate the stand-
ard error of the mean.Arthritis Research & Therapy    Vol 7 No 6    Bockermann et al.
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major bone remodelling after the inflammation went into remis-
sion (Fig. 2d,i), even though this strain is known to be prone to
development of osteophytes [27].
The inflammatory process, in contrast to CIA, was not limited
to synovial joints but also eroded vertebra and the annulus
fibrosus, together with the nucleus pulposus in mice of the
C3H background (Fig. 2g). Healthy vertebrae are shown in
Fig. 2f. B10.P mice, which share the MHC region with the
highly susceptible C3H.NB mice, were resistant to arthritis,
showing the strong influence of non-MHC genes. The MHC
congenic B10.Q strain, on the other hand, developed signifi-
cant but mild acute arthritis, whereas another MHC congenic
strain – B10.RIII – was also totally resistant to joint destruc-
tion. It should be noted that the B10.Q strain used in this study
is different from the B10.Q mouse available from Jackson Lab-
oratories, which has an arthritis-protective mutation of the
Tyk2 gene [28], which explains the earlier reported resistance
in these animals to G6PI-induced arthritis [21]. The (B10.Q ×
DBA/1)F1 mice developed arthritis almost as severe as that in
DBA/1 mice, showing that part of the genetic contribution
from DBA/1 dominates the suppressive B10.Q background
genes. Mice expressing the human DR4 (0401) molecule on
the B10 background were resistant to arthritis. These obser-
vations indicate that the most susceptible MHC haplotype is
H2q, which is similar to earlier observations in the CIA model
[29,30].
Because the highly susceptible C3H.NB strain harboured the
less susceptible MHC haplotype (H2p), we tested it in com-
parison with the C3H.Q strain, which is a MHC congenic
strain that carries the H2q haplotype. The C3H.Q strain devel-
oped slightly more chronic arthritis than the C3H.NB mice,
although the difference between the strains in single experi-
ments did not always achieve statistical significance because
of the high severity of arthritis in both strains (Fig. 1c).
A booster immunization after resolution of arthritis induced a
relapse in most strains (Fig. 1b), but this was milder than the
first arthritic episode and started at the exact same time after
immunization, suggesting that there is no memory effect from
the primary immunization.
Development of G6PI arthritis is associated with a strong 
antibody response to G6PI and a weak response to type 
II collagen
All arthritis susceptible mouse strains developed a strong anti-
body response to human G6PI (hG6PI; Fig. 3a). However, the
hG6PI specific antibody response did not always correlate
with arthritis severity; strong correlation was found only in the
C3H.NB strain (Table 1). The anti-G6PI antibody response
made use of all IgG isotypes (data not shown). ELISA plates
were also coated with recombinant mouse G6PI because
human G6PI was used for immunization. The antibody
responses were very similar using the two proteins (Fig. 3a,b).
To exclude the His-tag as an allogeneic B-cell epitope, we also
investigated the antibody response against a His-tag fusion
protein of hCK (Fig. 3d) and His-tag labelled recombinant Aq
as negative controls (data not shown). No significant response
Figure 2
Clinical and histological evaluation of arthritis Clinical and histological evaluation of arthritis. Clinical and histological 
evaluation demonstrates that arthritis induced with 200 µg glucose-6-
phosphate isomerase (G6PI) in complete Freund's adjuvant (CFA) 
leads to chronic destructive arthritis in mice on the C3H background. 
(a) Healthy C3H.Q hind foot. (b) A C3H.Q hind foot 90 days after dis-
ease induction. The digits are still red and swollen. After day 90 paws 
were fixated and decalcified for paraffin sectioning. Histopathology 
demonstrates the destructive character of the GPI-induced arthritis in 
C3H in comparison with DBA/1 mice. Both mice achieved clinical 
scores in their hind feet of 15. The C3H mouse developed (e) an irre-
versible destruction of their joints through invasive pannus tissue 
accompanied by new bone formation, (j) destroying the whole architec-
ture of the ankle, whereas DBA/1 mice have relatively intact joints, apart 
from (d) smaller erosions (arrows) and (i) hyperplasia. (c,h) Healthy 
control joints. The severity of the disease on the C3H background is 
also indicated by (g) the destruction of intervertebral structures such as 
the annulus fibrosus, nucleus pulposus and the vertebra themselves by 
inflammatory cells (arrow). (f) Healthy control tail. Staining with haema-
toxylin and erythrosine; original magnification 25× and 100×. af, annu-
lus fibrosus; np, nucleus pulposus; o, osteophytes; pa, pannus; sy, 
synovial membrane; ta, talus; ti, tibia.Available online http://arthritis-research.com/content/7/6/R1316
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Figure 3
Antibody analysis Antibody analysis. Indicated mouse strains were immunized with 200 µg human glucose-6-phosphate isomerase (hG6PI) in complete Freund's adju-
vant and bled at day 40 for antibody analysis. ELISA plates were coated with (a) 10 µg/ml hG6PI, (b) mouse G6PI (mG6PI), (c) collagen type II 
(CII), or (d) human creatine kinase (hCK). Sera from nonimmunized mice (n = 5) of different genetic backgrounds were used as negative controls. 
The figures show the optical density (OD) value for total IgG responses at a serum dilution of 1:1,000 for hG6PI, mG6PI and hCK (panels a, b and 
d) and 1:100 for CII (panel c). The results are represented as box plots, indicating the median, the 25th and 75th centiles as boxes, and the 10th 
and 90th centiles as whiskers. Outliers are indicated as circles.
Table 1
Correlation between specific IgG-total and accumulative score
Strain Anti-hG6PI versus score Anti-CII versus score n
Rho P value Rho P value
C3H.NB 0.917* 0.009* 0.793* 0.026* 9
B10.Q 0.402* 0.046* -0.094 0.614 26
(B10.Q × DBA1)F1 0.018 0.956 0.139 0.67 10
DBA/1 0.317 0.370 0.033 0.924 10
To investigate correlations between arthritis severity and antibody production the Spearman correlation test was applied. Mice of indicated strains 
were immunized with 200 µg glucose-6-phosphate isomerase (G6PI) in complete Freund's adjuvant. Blood was drawn at day 40 and analyzed by 
ELISA for anti-hG6PI and anti-CII total IgG responses, as shown in Fig. 1. The accumulative arthritis score until day 40 was tested for correlation 
with antibody production using the Spearman rank correlation test. A rho value close to 1 indicates correlation of high ranks for IgG with high 
ranks for arthritis scores; 0 indicates that there is no correlation between values; and a number close to -1 indicates that high ranks for one 
variable correlate with low ranks for the other. *Significant positive correlations.Arthritis Research & Therapy    Vol 7 No 6    Bockermann et al.
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for these antigens could be detected. That the response was
truly directed against conserved G6PI epitopes was also
confirmed by using tissue purified commercial (Sigma-Aldrich
Sweden AB, Stockholm, Sweden) rabbit G6PI (data not
shown).
Nevertheless, many of the strains used, such as B10.RIII and
B10.DR4, did not develop arthritis even though they exhibited
strong antibody responses against G6PI, indicating the pres-
ence of other protective factors. Interestingly, arthritis suscep-
tible strains developed significant titres to CII (Fig 3c), but
again only the C3H.NB mice exhibited a positive correlation
between anti-CII antibody response and arthritis severity
(Table 1).
Development of G6PI-induced arthritis is B-cell 
dependent
To determine conclusively whether B cells play a critical role in
the pathology of G6PI-induced arthritis we used mice with a
disrupted IgM gene, which are therefore deficient in mature B
cells. No arthritis developed in B-cell-deficient B10.Q mice
(Fig. 4a). C3H.Q µMT mice developed only very mild oedema
for no longer than 2 days (Fig. 4b), leaving no histological
changes (data not shown).
Discussion
Immunization with G6PI induces arthritis of various degrees of
severity and chronicity, depending on the mouse strain. Inter-
estingly, the C3H genetic background permits a chronically
active disease course that leads to loss of joint function. This
is an important feature of an animal model of RA because the
human disease is already chronic when it becomes diagnosed.
RA is most likely often preceded by many years of subclinical
inflammatory activity. This is not only reflected by raised C-
reactive protein levels but also by the production of autoanti-
bodies such as rheumatoid factors and antibodies to citrulli-
nated proteins [31-33]. The chronic disease course of arthritis
in C3H.Q and C3H.NB mice, induced with G6PI, will be useful
in the analysis of mechanisms of chronicity and as a model to
develop new therapeutic protocols.
Interestingly, the C3H background also allows a more severe
CIA [16,34]. In addition, in both models, the DBA/1 mouse
develops a severe but acute and self-limited type of arthritis.
Another striking similarity between the G6PI model and CIA is
the association with MHC. In both models the H2q haplotype
confers a more severe form of arthritis than does H2p. In the
CIA model this difference has been shown to be due to the Aq
molecule, which binds the immunodominant CII260–270 glyco-
peptide with greater affinity than the corresponding Ap mole-
cule [35]. It would therefore be of interest to identify the G6PI
peptide that binds to Aq and to investigate its affinity to the dif-
ferent MHC molecules, in analogy to the CII peptide. However,
a difference from CIA is that the H2r haplotype, despite a
strong anti-G6PI antibody response, does not confer suscep-
tibility to G6PI-induced arthritis, although in the CIA model the
association with H2r is dependent on binding and recognition
of peptides other than 260–270 [36]. Another apparent differ-
ence is that DR4 (DRB1*0401/DRA) expressing mice are sus-
ceptible to CIA [19,37] but not to G6PI-induced arthritis. This
is possibly due to a threshold effect, in which the mice devel-
oped a strong autoimmune response to G6PI but which, com-
bined with the relative nonpermissive B10 background, did not
lead to arthritis. It may not be unexpected that G6PI-induced
arthritis is critically dependent on functional B cells, as shown
by our findings in B-cell deficient µMT mice on the B10 and
the C3H backgrounds. However, it is interesting that a mild
transient oedema was observed in B-cell-deficient mice on the
highly arthritis susceptible C3H background.
Figure 4
Role of B cells in the pathology of G6PI-induced arthritis Role of B cells in the pathology of G6PI-induced arthritis. The role of B 
cells in the pathology of glucose-6-phosphate isomerase (G6PI)-
induced arthritis was addressed using B-cell deficient µMT mice on 
B10.Q and C3H.Q backgrounds. Mice aged between 6 and 7 weeks 
were immunized with 200 µg G6PI in complete Freund's adjuvant and 
scored for arthritis. (a) Five out of seven B10.Q mice developed arthri-
tis, whereas none of the six B10.Q µMT mice exhibited signs of inflam-
mation. (b) Four out of 12 C3H.Q µMT mice exhibited mild oedema for 
no longer than 48 hours, whereas all nine C3H.Q littermate control 
mice demonstrated a destructive inflammatory disease course. Error 
bars indicate the standard error of the mean.Available online http://arthritis-research.com/content/7/6/R1316
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It has been shown in the K/BxN transgenic model that anti-
G6PI serum antibodies readily transfer arthritis [4,6]. In the
protein-induced G6PI model, this has so far not been demon-
strated [21], and the antibody titres in the different strains do
not exhibit a convincing correlation with arthritis susceptibility.
Thus, high levels of antibodies to G6PI do not always lead to
arthritis, indicating that other pathogenic factors play a role.
Interestingly, a few mice with severe arthritis developed
detectable amounts of antibodies to CII. There is no evidence
for a cross-reactivity between G6PI and CII, and the most likely
explanation is an activation of an autoimmune response to car-
tilage-derived CII, as has been seen in pristine-induced arthri-
tis and in various spontaneous arthritides in mice [38-41].
On the C3H background the G6PI model is also useful in
investigating ankylosing spondylitis because it generates
inflammation of vertebral joints followed by ankylosis after a
single round of immunization. Careful serum analysis of
patients with different forms of arthritides revealed that G6PI-
specific antibodies may be identified not only in severe forms
of RA but also in ankylosing spondylitis and Reiter's syndrome
[15]. The G6PI-induced arthritis model on the C3H back-
ground demonstrates that an initial G6PI immune response is
sufficient to induce destructive activity in the spine. Which
C3H genetic factors actually contribute to this arthritis path-
way remain to be determined, and this needs a careful and
cautious analysis of the precise genetic background of any
mice used.
Our work over many years with congenic and transgenic mice
has made us aware of pitfalls relating to the purity of genetic
backgrounds. One should be careful in extrapolating data
without having full control over the genetic backgrounds. It is
not too surprising that, for instance, the C3H.He mice used by
Ji and coworkers [42] did not exhibit high sensitivity for their
serum transfer model, as might be suggested by our results.
Not only does the C3H.He mouse from Jackson, used by
those investigators, has a defect in the Toll-like receptor 4 that
renders it unresponsive to lipopolysaccharide stimulation, but
also it carries another MHC haplotype (H2-K) compared with
our congenic mice. Furthermore, it is likely that the different
MHC congenic inbred strains have accumulated mutations
over the years, as well as carrying several contaminating frag-
ments due to incomplete backcrossing. Bearing these prob-
lems in mind, we backcrossed our C3H.Q mice for several
generations to C3H.NB to be sure that we compared the
MHC effect only. Therefore, it will be of great interest in future
investigations to use a panel of highly controlled congenic
mice to identify chronicity factors in C3H mice.
In an examination of the IgG isotypes active in human Reiter's
syndrome, they appeared to be predominantly of the T-helper-
2-like isotype IgG4, equivalent to IgG1 in K/BxN mice [15]. It
will be interesting to investigate whether a T-helper-2 driven
immune response is responsible for the chronic severity and
spine involvement with the C3H background.
Taken together, there are several similarities but also differ-
ences between G6PI-induced arthritis and CIA. Most strik-
ingly, the genetic control in the two models allows only acute
arthritis in DBA/1 mice but a more chronic relapsing form in
mice of the C3H background. In the CIA model the B10 back-
ground allows chronic development of arthritis [43]. Interest-
ingly, both models appear to follow a central pathogenic
pathway that involves B-cell autoreactivity and arthritogenic
antibodies. Experiments using antibodies to CII and G6PI over
the years have shown extensive similarities [6,8,42,44-49].
The most obvious difference between the two models is the
tissue distribution of the autoantigen. G6PI is systemically dis-
tributed in the body because it is expressed intracellular in all
cells as an enzyme of glycolysis and can furthermore be
secreted. CII is also widely expressed during foetal develop-
ment (for review see Holmdahl and coworkers [50]). In the
adult CII expression is more restricted, mainly to cartilage (e.g.
in diarthrodial joints, larynx, spine and sternum). It is also
expressed in the vitreous body of the eye [50]. G6PI-induced
arthritis developed much earlier after immunization than did
CIA and with a stronger oedematous appearance, which could
extend into the knees, although no prominent histological
changes were observed in DBA/1 mice. Thus, in both CIA and
G6PI-induced arthritis the tissue distribution of the autoanti-
gen could not account for the specificity of the inflammatory
disease. In fact, models with unknown autoantigens, like
induction of arthritis with the alkane pristane, are also specific
in that the resulting inflammation only affects joints [51,52].
One important question to address is where the immune sys-
tem detects the autoantigen. The antigen might be differently
expressed in various tissues and be processed differently
depending on the kind of antigen-presenting cell. Another
issue to address is the role played by synovial tissue in diar-
throdial joints because these joints are predominantly
affected. The cartilage surface may be of importance for trig-
gering antibody-mediated inflammation, as shown for both
anti-CII and anti-G6PI antibodies. Taken together, we believe
that G6PI-induced arthritis is a very useful model for studies of
RA and it may represent a unique pathway, in particular with
respect to its autoantigen specificity and chronicity.
Conclusion
This study showed that G6PI-induced arthritis can be con-
verted into a chronic inflammatory arthritis model by using the
C3H genetic background. Mice of the C3H background also
develop arthritis in their vertebra, supporting a role for G6PI
reactivity in ankylosing spondylitis.
We conclude that G6PI has the ability to induce a chronic
from of arthritis, which is MHC associated and B-cell depend-Arthritis Research & Therapy    Vol 7 No 6    Bockermann et al.
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ent. Thus, there is a striking similarity between G6PI-induced
arthritis and the CIA model. Genetic factors determining chro-
nicity – a hallmark of RA – will be addressed using this model
in future experiments.
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